DISPOSITION AND METABOLISM OF RO-24-4736 IN THE RAT

Ro 24-4736, a new platelet activating factor antagonist, is currently under preclinical and clinical development. The tissue distribution of the C-14-label in male rats following a single intravenous dose of 1. 0 mg/kg of C-14-Ro 24-4736 indicated appreciable uptake by the liver, kidney, heart and gastrointestinal tract. Peak plasma and tissue conce ntrations were seen at 5 minutes after dosing except for the small int estine (4 hrs) and abdominal fat, stomach and large intestine (4 hrs). Thereafter, the C-14-label rapidly declined in all tissues. At 48 hou rs, only 3.5% of the dose was present in the tissues, and 6.1% in the lumen of the gastrointestinal tracts. The excretion of C-14 was essent ially completed; 94% of the administered C-14 was excreted in the fece s and 4.0% in the urine. Overall recoveries of the administered C-14 l abel ranged from 96 to 116%. The purified major C-14-labelled componen t in the fecal extracts yielded essentially the same NMR spectrum as a uthentic Ro 24-4736 which accounted for 11% of the dose. In vitro incu bations of Ro 24-4736 with rat liver 9S supernatant in an NADPH genera ting system produced two metabolites. NMR spectra indicated that one m etabolite was hydroxylated at carbon-1 while the other one contained a hydroxyl at carbon-10 of the parent molecule. Interestingly, the site s of hydroxylation were at carbons C-1, and C-10 bearing the protons g uarding the bay area of the phenanthrenoid ring, rather than carbons o f the phenyl-methyl-thienotriazolodiazepine moiety.